Press Releases

Press Releases

Press Releases

October 10, 2017
LONDON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics United Kingdom (UK) today announced that volanesorsen has been granted a Promising Innovative Medicine (PIM) Designation by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of familial chylomicronaemia
October 4, 2017
OTTAWA , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics Canada is pleased to announce the appointment of Nelly Komari , B. Pharm., MSc., as Medical Director.  Akcea Therapeutics Canada, the Canadian subsidiary of Akcea Therapeutics, Inc. , an affiliate of Ionis Pharmaceuticals, Inc.
September 12, 2017
Health Canada grants priority review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS OTTAWA , Sept. 12, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics Canada, the Canadian subsidiary of Akcea Therapeutics, Inc.
September 12, 2017
Health Canada grants priority review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
September 6, 2017
Appoints Canadian General Manager CAMBRIDGE, Mass. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid
September 5, 2017
Expansion of Akcea Leadership Further Strengthens Financial, Clinical and Commercial Foundation CAMBRIDGE, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. focused on developing and commercializing drugs to treat patients
August 31, 2017
CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced
August 29, 2017
CAMBRIDGE, Mass. , Aug. 29, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that
August 8, 2017
Marketing authorization application submitted to the European Medicines Agency for the approval of volanesorsen Cash balance of approximately $300 million to fund volanesorsen launch and cardiometabolic pipeline advancement Strategic investment of $75 million by Novartis and Ionis   CAMBRIDGE,
July 27, 2017
CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 27, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that a marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for volanesorsen